Evolus Inc
NASDAQ:EOLS

Watchlist Manager
Evolus Inc Logo
Evolus Inc
NASDAQ:EOLS
Watchlist
Price: 5.92 USD 0.17%
Market Cap: 383.7m USD

Relative Value

The Relative Value of one EOLS stock under the Base Case scenario is 19.7 USD. Compared to the current market price of 5.92 USD, Evolus Inc is Undervalued by 70%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EOLS Relative Value
Base Case
19.7 USD
Undervaluation 70%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
38
Median 3Y
3
Median 5Y
3.5
Industry
2.6
Forward
1.3
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-8
Industry
21.4
Forward
-13
vs History
vs Industry
Median 3Y
-14.3
Median 5Y
-11.9
Industry
16.4
vs History
vs Industry
1
Median 3Y
-12.8
Median 5Y
-11.7
Industry
22.8
vs History
vs Industry
0
Median 3Y
-13.9
Median 5Y
6.1
Industry
2.2
vs History
96
vs Industry
36
Median 3Y
3.3
Median 5Y
3.5
Industry
2.9
Forward
1.6
vs History
96
vs Industry
44
Median 3Y
5.1
Median 5Y
5.3
Industry
5.5
vs History
vs Industry
Median 3Y
-19.2
Median 5Y
-12.5
Industry
13
Forward
-39.5
vs History
vs Industry
Median 3Y
-16.5
Median 5Y
-11.1
Industry
16.5
Forward
-47.6
vs History
vs Industry
Median 3Y
-16.3
Median 5Y
-11.3
Industry
15.6
vs History
vs Industry
Median 3Y
-14
Median 5Y
-10.9
Industry
18.7
vs History
90
vs Industry
13
Median 3Y
5.2
Median 5Y
4.7
Industry
1.9

Multiples Across Competitors

EOLS Competitors Multiples
Evolus Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Evolus Inc
NASDAQ:EOLS
383.4m USD 1.3 -6.5 -15.2 -12.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.7 38 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.2B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
267.7B CHF 4.3 28.4 12.1 14.1
UK
AstraZeneca PLC
LSE:AZN
220.3B GBP 5.1 31.6 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
276B USD 4.3 14.5 10.3 12.2
CH
Novartis AG
SIX:NOVN
218.3B CHF 4.9 19.1 12.1 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
US
Evolus Inc
NASDAQ:EOLS
Average P/E: 25.1
Negative Multiple: -6.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Evolus Inc
NASDAQ:EOLS
Average EV/EBITDA: 440.1
Negative Multiple: -15.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.1
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Evolus Inc
NASDAQ:EOLS
Average EV/EBIT: 1 883.7
Negative Multiple: -12.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.1
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5